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The NO-cGMP signaling plays an important role in the regulation of striatal function
although the mechanisms of action of cGMP specifically in medium spiny neurons
(MSNs) remain unclear. Using genetically encoded fluorescent biosensors, including a
novel Epac-based sensor (EPAC-SH150) with increased sensitivity for cAMP, we analyze
the cGMP response to NO and whether it affected cAMP/PKA signaling in MSNs. The
Cygnet2 sensor for cGMP reported large responses to NO donors in both striatonigral
and striatopallidal MSNs, this cGMP signal was controlled partially by PDE2. At the level
of cAMP brief forskolin stimulations produced transient cAMP signals which differed
between D1 and D2 MSNs. NO inhibited these cAMP transients through cGMP-dependent
PDE2 activation, an effect that was translated and magnified downstream of cAMP, at
the level of PKA. PDE2 thus appears as a critical effector of NO which modulates the
post-synaptic response of MSNs to dopaminergic transmission.
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INTRODUCTION
Cyclic nucleotides control a range of cellular processes, particu-
larly in neurons where they transduce extracellular signals carried
by neuromodulators. The striatum is involved in reward, motor
control and action selection, and cyclic nucleotide signaling plays
a critical role in the normal function of this brain structure. While
the involvement of cAMP in striatal physiology is widely acknowl-
edged, much less is known on cGMP, although this signaling
cascade also plays a critical role in the regulation of striatal func-
tion (West and Tseng, 2011). Medium spiny neurons (MSNs) in
the striatum constitute 95% of the neuronal types, approximately
half of which are anatomically defined as the “direct pathway” and
express dopamine type 1 receptors (D1). This receptor is pos-
itively coupled to cAMP production. The other half of MSNs,
defined as the “indirect pathway,” express high levels of dopamine
type 2 receptors (D2) and adenosine A2A receptors (Le Moine
and Bloch, 1995; Bateup et al., 2008; Bertran-Gonzalez et al.,
2008). D2 receptors are negatively coupled to adenylyl cyclases
(AC) and therefore inhibit cAMP production while the A2A recep-
tors are positively coupled to AC and increase cAMP levels. The
segregation between D1 and A2A expressing neurons is clearly
visualized using cAMP/PKA biosensors (Castro et al., 2013).
The functional effects of the cAMP signaling cascade has been
widely documented in the striatum (Hervé and Girault, 2005)
but much less is know about the cGMP signaling. cGMP is pro-
duced by the NO receptor, aka soluble guanylyl cyclase (sGC), in
response to nitric oxide (NO), and NO/cGMP signaling regulates
a number of neurobiological processes (Garthwaite, 2008). sGC
is highly expressed in the striatum (Ariano et al., 1982; Matsuoka
et al., 1992; Ding et al., 2004) while the NO producing enzyme
nNOS is highly expressed by a fraction of striatal interneurons
(Vincent and Kimura, 1992; Rushlow et al., 1995; Kawaguchi,
1997; Vincent, 2000). It is commonly accepted that NO produced
by NOS interneurons diffuses throughout the striatal complex
and increases corticostriatal and dopaminergic synaptic transmis-
sion via a sGC-cGMP dependent mechanism (West et al., 2002;
West and Grace, 2004; West and Tseng, 2011). In addition, NO
diffuses into the dendrites of MSNs modulating corticostriatal
synaptic plasticity in vitro (Calabresi et al., 1999, 2000) and in vivo
(West and Grace, 2004). While these effects are clearly mediated
by cGMP, the downstream effectors of cGMP, often assumed to
be the cGMP-dependent protein kinase (PKG), remain uncertain,
since only moderate levels of expression have been reported in
the striatum (el-Husseini et al., 1995; El-Husseini et al., 1999; de
Vente et al., 2001) and CNG expression has not been reported in
the striatum (Wei et al., 1998).
An important part of the signal transduction process is the
rapid degradation of the cyclic nucleotides by cyclic nucleotide
phosphodiesterases (PDEs). PDE2mRNA and protein are present
at high levels in the striatum (Repaske et al., 1993; Van Staveren
et al., 2003) and functionally active (Wykes et al., 2002; Lin et al.,
2010). PDE2 has dual enzymatic activity allowing to hydrolyze
both cAMP and cGMP (Erneux et al., 1981; Martins et al.,
1982). A characteristic feature of PDE2 is the positive cooper-
ativity of the substrate cGMP: in the absence of cGMP, PDE2
activity is low, and the binding of sub-micromolar cGMP to
the regulatory GAF-B domain of the amino-terminus of PDE2
results in a 5-fold increase in cAMP hydrolysis rate (Martins
et al., 1982; Martinez et al., 2002). The interplay between cAMP
and cGMP signals through PDE2 has been well characterized
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mainly in the cardiovascular system (Maurice, 2005; Nikolaev
et al., 2005), where cGMP-mediated regulation of cAMP occurs
in a spatially confined cellular compartment and depends on
the source of cGMP (Castro et al., 2006; Stangherlin et al.,
2011). Regulation of cyclic nucleotides by PDE2 has already been
shown in thalamic (Hepp et al., 2007) and striatal neurons (Lin
et al., 2010), although in the striatum the role of PDE2 at the
cellular level remained to be analyzed. Here, we improved the
TEpacVV cAMP sensor (Klarenbeek et al., 2011) which allowed
us to analyze the dynamics of cAMP regulation in striatal neu-
rons and to determine the functional effect of cGMP on this
signal.
Our data reveal that NO/cGMP signaling reduces the cAMP
signals in both striatonigral and striatopallidal MSNs through the
activation of PDE2. This inhibitory effect propagates downstream
to PKA, leading to an inhibition of the PKA response to D1 stim-
ulation. In addition, we found that the dynamics of the cAMP
responses are not identical in MSNs, with striatopallidal neu-
rons displaying larger and longer lasting cAMP transients than
striatonigral MSNs.
MATERIALS AND METHODS
BIOSENSOR CONSTRUCT AND VALIDATION
From the starting material TEpacVV (Klarenbeek et al., 2011),
numbered Epac-SH74 in our database, we first exchanged
mTurquoise for mTurqouise2 using the same protocol as in
Klarenbeek et al., creating Epac-SH126. Second the Q270E
mutation was introduced by cutting the Epac-SH126 with PshAI
en BstEII inserting annealed oligo’s forward primer: GTGACCCA
TGGCAAGGGGCTGGTGACCACCCTGCATGAGGGAGATGAT
TTTGGAGAGCTGGCTCTGGTCAATGATGCACCCCGGGCAG




SH134. Third the acceptor was inserted as a PCR-product of
cp174Citrine using forward primer: GGGGCTAGCGAGCTCAT
GGACGGCGGCGTGCA and reverse primer: CGAATTCGG
CTCGATGTTGTGGCGGAT digested with NheI and EcoRI,
yielding Epac-SH150. All constructs were checked by sequence
analysis. Hek293 embryonal kidney cells (American Type Culture
Collection crl-1573) were cultured in DMEM supplemented
with 10% FCS and antibiotics. Cells were seeded in six 15 cm2
plates and transfected with 10µg DNA per plate using calcium
phosphate or fugene transfection agent. After overnight expres-
sion, cells were resuspended in 1ml hypotonic buffer (PBS: H2O
1: 2) and homogenized with a Downs piston. The homogenate
was centrifuged for 10min at 4◦. The supernatant was corrected
toward isotonic conditions using a concentrated stock of PBS.
The supernatant was diluted 10 times in buffer containing
(in mM) 150 KCl, 5 NaCl, 1 MgCl2 10 HEPES pH 7.2, with a total
volume of 2ml in a stirred cuvette of a PTI Quantamaster dual
channel spectrofluorimeter (Lawrenceville, NJ). Small volumes
of cAMP from concentrated stocks were added repeatedly to
titrate in cAMP, total added volume 40µl. The response to cAMP
was quantified as the ratio between YFP (530 ± 10 nm) and CFP
(490 ± 10 nm), when excited with 420 ± 3 nm.
BRAIN SLICE PREPARATION
Wild-type C57Bl/6J mice were obtained from Janvier (Le Genest
Saint Isle, France). Mice were maintained in a 12 h light–12 h
dark cycle, in stable conditions of temperature (22◦C), with food
and water available ad libitum. All the experiments were per-
formed according to French Ministry of Agriculture and Forestry
guidelines for handling animals (87–848◦).
Brain slices were prepared from male mice aged from 9 to 13
days, as previously described (Castro et al., 2013). Coronal brain
slices of 300µm thickness were cut with a VT1200S microtome
(Leica, Germany). Slices were prepared in an ice-cold solution of
the following composition: 125mM NaCl, 0.4mM CaCl2, 1mM
MgCl2, 1.25mM NaH2PO4, 26mM NaHCO3, 25mM glucose
and 1mM kynurenic acid, saturated with 5% CO2 and 95%
O2. The slices were incubated in this solution for 30min and
then placed on a Millicell-CM membrane (Millipore) in cul-
ture medium (50% Minimum Essential Medium, 50% Hanks’
Balanced Salt Solution, 6.5 g/l glucose, penicillin-streptomycin,
Invitrogen). We used the Sindbis virus as a vector to induce
expression of the various probes (Ehrengruber et al., 1999).
The sindbis viral vector for AKAR3 and Cygnet2 was prepared
as as previously described (Gervasi et al., 2007; Hepp et al., 2007).
Similarly, the Epac-SH150 digested with HindIII was inserted into
pSinRep5 (Invitrogen, San Diego, CA) digested with StuI and
made blunt by Klenow and HpaI.
Compared to our previous work (Castro et al., 2013), the viral
vector was diluted to decrease the number of infected neurons
and thus facilitate individual cell measurement. Slices were incu-
bated overnight at 35◦C under an atmosphere containing 5%
CO2. Before the experiment, slices were incubated for 30min in
the recording solution (identical to the solution used for cutting,
except that the calcium concentration was 2mM and kynurenic
acid was omitted). During recordings, brain slices were continu-
ously perfused with this solution saturated with 5%CO2/95%O2,
at a rate of 2ml/min, in a recording chamber of ∼1ml volume
maintained at 32◦C. The viability of the neurons in these experi-
mental conditions have been checked by patch-clamp recording,
which showed electrical activity to be normal (Gervasi et al., 2007;
Castro et al., 2010).
OPTICAL RECORDINGS ON BRAIN SLICES
Recordings were made on MSNs, that constitute 95% of neu-
rons in the striatum. Large neurons, presumably cholinergic
interneurones, were excluded (i.e., diameter larger than 14µm).
Wide-field images were obtained with an Olympus BX50WI
or BX51WI upright microscope with a 20×0.5 NA or a 40 ×
0.8 NA water-immersion objective and an ORCA-AG camera
(Hamamatsu). Images were acquired with iVision (Biovision,
Exton, PA, USA). The excitation and dichroic filters were D436/20
and 455dcxt. Signals were acquired by alternating the emission fil-
ters, HQ480/40 for CFP, and D535/40 for YFP, with a filter wheel
(Sutter Instruments, Novato, CA, USA). All filters were obtained
from Chroma Technology (Brattleboro, VT, USA). Image acqui-
sition was triggered manually, except for kinetics measurement
where images were acquired automatically with 3–5 s intervals.
Images were analyzed with custom routines written in the
IGOR Pro environment (Wavemetrics, Lake Oswego, OR, USA).
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The emission ratio was calculated for each pixel: F535/F480 for
AKAR3 and F480/F535 for Epac-SH150. Pseudocolor images dis-
play the ratio value coded in hue and the fluorescence intensity
coded in intensity. A calibration square indicates the intensity val-
ues from left to right and the ratio values from bottom to top.
The size of the square indicates the scale of the image in microns.
No correction for bleed-through or direct excitation of the accep-
tor was applied and the ratio changes in our conditions therefore
appear smaller than those reported by other studies in which such
corrections were applied.
FAST DRUG APPLICATION
A fast focal application system was previously used for kinetic
studies (Gervasi et al., 2007; Castro et al., 2013). A glass pipette
(100–150µm tip diameter) was placed 300µm to the side of and
200µmabove the brain slice and ejected the drug contained in the
same solution as the bath. Dopamine uncaging was performed
with UV light at 360 nm applied in wide-field mode (UVILED,
Rapp OptoElectronic, Hamburg, Germany). Image acquisition
in these fast wide-field recordings was automatic at a frequency
ranging from 0.2 to 0.3Hz. Image acquisition was otherwise
triggered manually by the user.
DATA ANALYSIS AND STATISTICS
Ratiometric quantification was performed with a ratio value
between the Rmin and Rmax values, which correspond to the
minimal ratio value (no biological signal) and maximal response
(saturated biosensor) (Grynkiewicz et al., 1985; Börner et al.,
2011). The baseline ratio in control conditions was considered
to be equal to Rmin because adenylyl cyclase inhibition with
50µM SQ22536 and guanylyl cyclase inhibition with 10µM
ODQ yielded no ratio decrease with Cygnet2 biosensor. The max-
imal response (Rmax, corresponding to biosensor saturation) was
determined for each neuron at the end of the recording. This
level was determined by applying 13µM forskolin (for cAMP) or
SNAP (for cGMP) in the presence of the broad-spectrum phos-
phodiesterase inhibitor IBMX (200µM). Absolute ratio values
differed between cells [as shown with the mutant biosensor in
Castro et al. (2013)], so the amplitude of the response to recep-
tor stimulation was quantified for each neuron as the fractional
change in ratio from its own baseline (Rmin) and maximal final
ratio response (Rmax).
Measurements were performed on regions of interest and
some of the signal measured on a region of interest comes from
out-of-focus neurons. Regions of interest which displayed clear
responses to both SKF38393 and CGS21680 and which there-
fore contained fluorescence signal from out of focus cells were
discarded from our analysis.
Kinetic parameters (amplitude, tmax and t1/2off) were deter-
mined using IGORPro environment (Wavemetrics, LakeOswego,
OR, USA). tmax values were determined as the time to reach the
peak of the response and the t1/2off represents the time to reach a
half of the recovery of the response.
We analyzed at least four neurons per brain slice, with n
indicating the number of independent neurons tested. Unpaired
two-tailed student’s t-tests were used for statistical comparisons.
Differences were considered significant when P < 0.001.
DRUGS
SKF38393 hydrobromide, CGS21680 hydrochloride, 3-isobutyl-
1-methylxanthine (IBMX), rolipram, NPEC-caged dopamine
[(N)-1-(2-nitrophenyl) ethylcarboxy-3, 4-dihydroxyphenethyl
amine], and forskolin were obtained from Tocris Cookson
(Bristol, UK); 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one
(ODQ), S-nitroso-N-acetyl-D,L-penicillamine (SNAP), diethy-
lamine NO (DEANO), erythro-9-(2-hydroxy-3-nonyl)-adenine
(EHNA), BAY-60–7550 were obtained from Sigma-Aldrich (St
Quentin Fallavier, France); BAY60–7550 was obtained from
Cayman (Teaduspargi, Estonia).
RESULTS
NO ACTIVATES THE sGC/cGMP SIGNALING CASCADE IN MSNs
We used the cGMP sensor Cygnet2 (Honda et al., 2001) to
determine whether NO donors increase cGMP concentration
in MSNs. The NO donor S-nitroso-N-acetyl-D,L-penicillamine
(SNAP, 100µM) induced a large increase in the F480/F535 emis-
sion ratio of all the cygnet-expressing MSNs (Figure 1A). This
signal reversed with the washout of the drug and a second cGMP
response could be elicited from the same cells, showing that the
NO-cGMP signaling pathway can be activated repeatedly over the
time-course of our recordings.
The steady-state cGMP level upon sGC stimulation depends
on the relative activities of sGC and cGMP degradation medi-
ated by PDEs. In the presence of the NO donor, the non-specific
PDE inhibitor IBMX (200µM) increased the ratio to a higher
steady-state level, showing that PDE activities determine the
steady-state cGMP level reached upon NO-mediated sGC stim-
ulation. SNAP alone increased the emission ratio to 67 ± 8%
(n = 332) of this maximal response. Similar responses (71 ±
20%; n = 145) were obtained with the NO donor diethylamine
NO (DEANO, 100µM). As expected, sGC inhibition by ODQ
(10µM) prevented the response to SNAP and SNAP plus IBMX
(Figure 1B).
Previous studies performed with dissociated striatal neurons
demonstrated that PDE2 regulates the cGMP responses to NO
donors (Wykes et al., 2002; Lin et al., 2010). We tested the effect
of PDE2 inhibition in our brain slice preparation and in all tested
MSNs, the application of the PDE2 inhibitor EHNA (10µM),
added on top of the SNAP response, induced a further increase
of the cGMP signal, rising from 67 ± 8% (n = 332) to 90 ± 5%
(n = 151) of the maximal response obtained in the presence of
IBMX (Figures 1C,D). Like IBMX, EHNA alone had no effect on
basal cGMP levels.
These results confirm that PDE2 is critical in the regulation
of the cGMP signals in MSNs of the dorsal striatum upon sGC
stimulation.
A NEW BIOSENSOR TO MEASURE cAMP SIGNALS IN THE STRIATUM
Since cGMP increases PDE2 activity which also hydrolyzes cAMP,
we wanted to precisely monitor whether PDE2 controlled cAMP
levels in striatopallidal and striatonigral MSN. The recently pub-
lished TEpacVV (Epac-SH126) exhibits one of the largest ratio
changes known to date for a genetically-encoded biosensors
(Klarenbeek et al., 2011) but we considered that its relatively
low sensitivity for cAMP may be limiting. We have prepared a
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FIGURE 1 | Cygnet reports increases in cyclic GMP concentration in all
medium spiny neurons of the striatum in response to soluble guanylyl
cyclase activation. (A–C) Striatal neurons in a mouse brain slice expressing
Cygnet2 sensor and imaged by wide-field microscopy. (A) Images show the
raw fluorescence at 535 nm (left in gray scale) and the ratio (in pseudocolor),
indicating the ratiometric change of Cygnet2 reporting the binding of cGMP,
at the times indicated by the corresponding arrows on the graph below. Each
trace on the graph indicates the F480/F535 emission ratio measurement on
regions indicated by the color contour drawn on the raw image; the thick
black line represents the average of all the traces. The NO donor SNAP
(100µM) induced a strong increase in the ratio in all MSNs visible in the field.
SNAP + IBMX (200µM) induced a maximal increase in the ratio response.
(B) The responses to SNAP and SNAP + IBMX were completely blocked by
the soluble guanylyl cyclase blocker ODQ (10µM). (C) After the activation of
sGC with SNAP, the PDE2 inhibitor EHNA (10µM) increased the cGMP signal
to a level that corresponded to the maximal response. (D) The amplitude
measured with the Cygnet2 biosensor was normalized with respect to the
maximal SNAP + IBMX response and plotted as a histogram. Error bars
indicate s.e.m.; the numbers of tested neurons are indicated above each bar.
Unpaired two-tailed t-tests were carried out for comparisons with control
conditions (∗) and with SNAP alone (#), and differences were considered
significant when P < 0.05.
series of new Epac-based cAMP biosensors in which the donor
was replaced by mTurquoise2, which has a higher quantum
yield, longer lifetime and is more photo stable than mTurquoise
(Goedhart et al., 2012). The Q270E mutation (Dao et al., 2006)
was introduced in the cAMP binding site of the cAMP-binding
domain of Epac1 to increase its affinity for cAMP. This sensor,
called Epac-SH134 showed increased sensitivity to cAMP as com-
pared to the previous version (EC50 was 4.4 ± 0.3 vs. 10.7 ±
0.8µM, n = 5, p < 0.01, two-tailed paired t-test; Figure 2A).
This sensor was further improved by replacing the acceptor
cpVenus-Venus with a single circular permutation of Citrine
(cp174Citrine), chosen for optimal resistance to pH changes
and brightness. This sensor called Epac-SH150 showed a large
change in emission spectrum upon cAMP binding (Figure 2B)
and proved suitable to directly address the dynamics of cAMP
in MSNs in the striatum (Figure 2C). A detailed characteriza-
tion of this and other new cAMP sensors will be published
elsewhere.
As shown previously with PKA and cAMP biosensors with
two-photon microscopy (Castro et al., 2013), activation of the
D1 receptors with a saturating (1µM) dose of SKF38393 strongly
increased the F480/F535 emission ratio in one population of
MSNs called hereafter D1 neurons. In addition, the activation of
the A2A receptors with a saturating (1µM) dose of CGS21680
increased the emission ratio in the remaining neuronal pop-
ulation, the D2 neurons (Figure 2C). With low viral infection
levels, wide-field imaging thus allowed a sufficient cell separa-
tion to distinguish between the D1 and D2 neurons. The D1
response decreased with prolonged exposure to the agonist, prob-
ably a consequence of D1 receptor desensitization. In contrast,
the response to CGS21680 reached a stable steady-state level.
Both responses were not maximal, as the addition of the adeny-
lyl cyclase activator forskolin (FSK, 13µM) further increased the
ratio response, consistent with the wide cAMP sensitivity range
of this new biosensor. Addition of 200µM IBMX to forskolin
produced a small additional response, considered as the maxi-
mal ratio response Rmax (see methods). On average, SKF38393,
CGS21680, and FSK increased the emission ration to 51 ± 2 %
(n = 32), 27 ± 1 % (n = 29) and 95 ± 1% (n = 48) of the
maximal response to forskolin and IBMX (Figure 2D).
BRIEF ADENYLYL CYCLASE ACTIVATION IN D1 AND D2 NEURONS
This imaging method thus allowed us to analyze the cAMP sig-
nal in identified D1 or D2 MSNs and we set up a protocol for
transient adenylyl cyclase stimulation to analyze the onset, which
mostly reflect cAMP synthesis, and the decay, which is mostly
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FIGURE 2 | The Epac-SH150 sensor reported large cAMP signals in D1
and D2 MSNs. The TEpacVV sensor (labeled Epac-SH126) was mutated to
increase its sensitivity for cAMP, yielding Epac-SH134; representative
dose-response curves for both sensors are presented in (A). The acceptor
was then changed for a cp174Citrine, yielding Epac-SH150. The emission
spectrum of Epac-SH150 in the absence and in the presence of saturating
(100µM) cAMP is presented in (B). (C) Medium spiny neurons (MSNs) in
a mouse brain slice were transfected for expression of Epac-SH150 and
imaged with wide field microscopy. Images show the raw fluorescence at
535 nm (left, in gray scale) and the ratio (in pseudocolor) indicating the
ratiometric change of Epac-SH150 reporting the binding of cAMP, at the
times indicated by the arrows on the graph below. Each trace on the graph
indicates the F480/F535 emission ratio measurement on regions indicated
by the color contour drawn on the raw image; the thick black line
represents the average of all the traces in the two different groups. The
D1 receptor activator, SKF38393 (1µM), induced a transient ratio increase
in neurons thereby identified as D1 MSNs; activation of the A2A receptor
with CGS21680 (1µM) induced a sustained cAMP response in neurons
thereby identified as D2 MSNs. FSK + IBMX induced a ratio increase used
as 100% value in normalization. (D) The amplitude of the responses to
SKF38393 and CGS21680 was measured with the Epac-SH150 biosensor,
normalized with respect to the maximal FSK + IBMX response and plotted
as a histogram. The cAMP response to D1 receptor stimulation
(SKF38393) was significantly stronger than the response to D2 receptor
stimulation. Error bars indicate the s.e.m.; the number of tested neurons is
indicated above each bar.
governed by PDEs activities. Because the activation of D1 or A2A
receptors induced cAMP signals that differed in amplitude and
kinetics, we examined the responses to direct stimulation of AC
by forskolin, thereby analyzing the cAMP signal independently of
receptors. We used a fast focal application system to apply 10-s
pulses of forskolin (FSK) while monitoring the cAMP response,
and bath application of SKF38393 and CGS21680 at the end of the
recording to identify D1 and D2 neurons (Figure 3A). For both
D1 and D2 MSNs, brief forskolin stimulation resulted in a tran-
sient increase in Epac-SH150 signal, which could be reproduced
several times with no significant change in amplitude or kinet-
ics. These forskolin-induced cAMP transients differed between
the two types of MSNs in their amplitude and decay kinetics
(Figure 3B): D1 MSNs generated a cAMP transient that reached
67 ± 10% of Rmax and had a t1/2off of 2.5 ± 0.4min (n = 112;
see method for t1/2off definition); D2 neurons displayed a larger
cAMP signal that reached 79 ± 9% of Rmax and lasted two times
longer than the response in D1 neurons with a t1/2off of 4.3 ±
0.8min (n = 122); both amplitude and t1/2off were statistically
different from D1 (unpaired two-tailed t-test, P < 0.0001; see
Table 1).
We thought that this difference might result from regulation of
cAMP levels by PDEs, including PDE2. We observed that inhibi-
tion of PDE2 with EHNA increased the amplitude and prolonged
the decay of the forskolin-induced cAMP transients exclusively
in D2 MSNs (Figure 3C). No effect was observed in D1 MSNs,
despite the expression of PDE2 in these neurons (Figure 3D) (Lin
et al., 2010). Because PDE2 inhibition exacerbates the differences
between D1 and D2 MSNs, we hypothesized that other PDE activ-
ities differently regulate the cAMP signals in these neurons. We
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FIGURE 3 | Brief (10 s) application of FSK (13µM) produced stronger
and longer lasting cAMP responses in D2 MSNs than in D1 MSNs.
(A,C,E) cAMP signals were measured in wide-field imaging with
Epac-SH150 biosensor during the application of a 10 s pulse of FSK alone
(A), in the presence of EHNA (C) or IBMX (E). Each trace on the graph
indicate the Epac-SH150 emission ratio of an individual neuron. Traces were
separated on the basis of their response to the A2A agonist CGS21680
(1µM) or D1 agonist SKF38393 (1µM). (B) Mean responses in D1 (n = 112)
and D2 (n = 122) MSNs to brief FSK stimulation. (D,F) Mean responses in
D1 and D2 to brief FSK stimulation in the presence of EHNA (10µM) or
IBMX (200µM). Thin dashed and solid lines represent the mean responses
in D1 and D2 MSNs to brief FSK alone, for comparison. IBMX strongly
attenuated the differences between D1 (n = 17) and D2 (n = 21) MSNs.
EHNA increased the cAMP signaling in D2 MSNs (n = 19), but had no
effect in D1 cells (n = 19). Markers are plotted sparsely for clarity; error bars
represent SD.
tested this hypothesis by inhibiting most of PDE activities with
IBMX (Figures 3E,F). Application of IBMX alone increased basal
cAMP levels in both type of cells [28 ± 3% (n = 17) for D1
MSNs and 33 ± 3% (n = 21) for D2MSNs], showing that adeny-
lyl cyclase constitutively active. When most PDEs were blocked,
the cAMP transient induced with 10 s FSK was larger in ampli-
tude and its duration was considerably prolonged. The difference
in kinetics between D1 and D2 was almost obliterated, demon-
strating that phosphodiesterase activities differ between D1 and
D2 neurons. The slope of the 10–80% onset of the cAMP tran-
sient in the presence of IBMX was measured and showed no
statistical difference between D1 and D2 neurons (0.020 ± 0.005,
n = 17 for D1 MSNs vs. 0.023 ± 0.007, n = 20 for D2 MSNs,
expressed in ratio units per second, p = 0.199). This suggests that
the rate of cAMP synthesis is similar in both cell types. Further
work is needed to identify the specific contribution of each PDEs
in determining the shape of transient cAMP signals in D1 and
D2 MSNs.
PDE2 ACTIVATION BY cGMP LIMITS cAMP ACCUMULATION IN BOTH
D1 AND D2 MSNs
We then tested whether increasing PDE2 activity with cGMP
affected cAMP signaling in MSNs: we compared the cAMP tran-
sients in the absence and in the presence of the NO donor SNAP
(100µM). Application of SNAP in the bath had no effect per se
on basal cAMP signals (Figure 4A). However, the cAMP transient
was reduced in amplitude by about 20–30% in both striatonigral
and striatopallidal MSNs (Figure 4B; Table 1). The decay time-
course, however, did not change significantly from the respective
control (Figure 4B; Table 1).
This negative control exerted by NO was abolished when the
PDE2 inhibitor EHNA (10µM) was applied simultaneously with
the NO donor SNAP (100µM) (Figures 4C,D; Table 1). The
application of EHNA alone or in the presence of SNAP had
no effect on basal cAMP signal (Figure 4C). Since EHNA also
inhibits adenosine deaminase, we also tested the specific PDE2
inhibitor BAY60-7550 at 100 nM (Figures 4E,F): this drug also
blocked the inhibitory effect of NO donors on cAMP transients.
These results show that the inhibitory crosstalk exerted by cGMP
on cAMP transients is mediated by PDE2.
Table 1 | Kinetic parameters of the cAMP responses to FSK in MSNs.
D1 D2
Amplitude (%) t1/2off (min) tmax (s) n Amplitude (%) t1/2off (min) tmax (s) n
FSK 67 ± 10 2.6 ± 0.4 52 ± 10 112 79 ± 9 4.3 ± 0.8 51 ± 8 122
FSK + SNAP 41 ± 8 2.9 ± 0.6 54 ± 9 45 62 ± 7 4.0 ± 0.5 53 ± 7 48
FSK + EHNA 72 ± 8 2.5 ± 0.6 49 ± 7 19 91 ± 5 5.4 ± 0.8 55 ± 9 19
FSK + SNAP + EHNA 66 ± 9 2.6 ± 0.7 58 ± 13 46 84 ± 6 5.2 ± 1.1 54 ± 7 44
FSK + SNAP + Bay 607,550 60 ± 12 2.0 ± 0.3 46 ± 10 38 84 ± 12 5.3 ± 2.2 59 ± 9 25
cAMP signals were measure in wide-field imaging with Epac-SH150 biosensor during the application of a 10 s pulse of Forskoline (FSK, 13µM) alone or in the
presence of SNAP (100µM), EHNA (10µM), SNAP + EHNA and SNAP + Bay 607,550. The table shows the means (±SD) of the amplitudes, the tmax and t1/2off in
each experimental condition. n indicate the number of tested neurons.
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FIGURE 4 | SNAP reduces the cAMP/PKA signal in both D1 and D2
MSNs. cAMP signals were measure in wide-field imaging with Epac-SH150
biosensor during the application of a 10 s pulse of Forskolin (FSK, 13µM).
(A) Activation of soluble guanylyl cyclase with SNAP (100µM) strongly
reduced the amplitude of the cAMP response induced by brief (10 s) FSK
application in both D1 and D2 MSNs. Inhibition of PDE2 with EHNA (10µM)
(C) or Bay 607,550 (100 nM) (E) abolished the effect of SNAP on the cAMP
response. (B) Mean responses in D1 (n = 45) and D2 (n = 48) MSNs to
brief FSK stimulation in the presence of SNAP. (D) Mean responses in D1
(n = 46) and D2 (n = 44) MSNs to brief FSK stimulation in the presence of
SNAP plus EHNA; (F) Mean responses in D1 (n = 38) and D2 (n = 25)
MSNs to brief FSK stimulation in the presence of SNAP plus Bay 607,550.
(B,D,F) dashed and solid lines represent the average response to brief FSK
alone in D1 and D2 MSNs, respectively. Markers are plotted sparsely for
clarity; error bars represent SD.
THE NO/cGMP/PDE2 PATHWAY LIMITS PKA ACTIVATION UPON A
SUB-SECOND DOPAMINE SIGNAL
Finally, we checked whether the negative regulation exerted by
cGMP on the cAMP signal was sufficient to down-regulate PKA
activity. Physiological activation of D1-like receptors is asso-
ciated with phasic dopamine release related to a reward or
novelty (Garris and Wightman, 1994; Gonon, 1997; Schultz
and Dickinson, 2000). We mimicked phasic dopamine signals
by uncaging NPEC-dopamine with a flash of UV light of 1 s
duration while monitoring PKA activity with AKAR3. At the
end of the experiment, bath application of SKF38393 allowed
for the identification of D1 neurons (Figure 5A). D2 neurons,
which did not respond to dopamine uncaging or SKF38393,
were ignored. As already described (Castro et al., 2013), D1
MSNs displayed a large and transient response to 1 s dopamine
uncaging that reached 90 ± 2% n = 84 of the maximal steady-
state response to SKF38393 response (Figure 5B). In the presence
FIGURE 5 | SNAP inhibits the PKA response to brief (1 s) dopamine
uncaging in D1 MSNs. (A) MSNs expressing AKAR3 were imaged in
wide-field microscopy to measure the PKA response to dopamine. Arrows
indicate the UV flash. Flash photolysis of caged dopamine
(NPEC-dopamine, 5µM in the bath) induced a transient ratio increase.
SNAP decreased this response, and the PDE2 inhibitor EHNA (10µM)
restored the response to caged dopamine to its initial level. (B) Mean
responses in D1 to 1s UV flash alone (n = 84), in the presence of SNAP
(n = 80) and SNAP + EHNA (n = 74). For each flash, responses were
normalized with respect to the steady-state response to SKF38393.
Markers are plotted sparsely for clarity; error bars represent SD.
of the NO donor SNAP, the amplitude of the PKA signal was
decreased by 45% (42 ± 3% n = 80). PDE2 inhibition by 10µM
EHNA reverted the inhibitory effect of SNAP (93 ± 4% n = 74)
showing that PDE2 is indeed the mediator of this inhibitory
effect.
Interestingly, the inhibitory effect of SNAP appeared larger
at the level of PKA than at the level of cAMP, showing that a
moderate change in cAMP dynamics is amplified at the PKA level.
DISCUSSION
Previous studies have clearly highlighted NO/cGMP as a key
player in detecting and reinforcing corticostriatal glutamatergic
and dopaminergic neurotransmission (Calabresi et al., 2007;West
and Tseng, 2011). In this report, we highlight the importance of
the post-synaptic level where NO affects the integrative proper-
ties of MSNs. Our data demonstrate the functional importance of
PDE2 as a target of the NO/cGMP pathway, and its importance
in the regulation of transient cAMP responses. With the high
resolution provided by our improved biosensor, we also high-
light significant differences between D1 and D2 MSNs in their
response to transient AC stimulation, a difference that results
from differences in phosphodiesterase activities.
PDE2 AS A MAJOR TARGET OF cGMP IN THE STRIATUM
The physiological effects of the NO/cGMP pathway largely
depend on its targets which include cGMP-gated ion channels,
cGMP-dependent kinase protein (PKG) and cGMP-regulated
PDEs. Interestingly, brain regions such as the hippocampus and
the striatum which express high levels of sGC (Matsuoka et al.,
1992; Ding et al., 2004), do not express much PKG protein (el-
Husseini et al., 1995; El-Husseini et al., 1999) but very high levels
of PDE2 (Repaske et al., 1993; Van Staveren et al., 2003). This sug-
gests that the major role of cGMPmay be to regulate cAMP levels
via PDE2 activation, rather than to directly activate PKG. This
hypothesis is clearly supported by our experiments which show
that one major functional effect of NO-triggered cGMP produc-
tion is the activation of PDE2 which then strongly reduce the
cAMP response in both D1 and D2 neurons.
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The inhibitory effect of NO on the transient response was
much more pronounced when considering the effect at the PKA
level than at the cAMP level. This results appears counterintu-
itive as one might expect PKA to smooth-out small variations in
cAMP concentration. This non-linearity in signal transduction
from cAMP level to PKA level may result from positive feed-
back controls such as that mediated by DARPP-32: DARPP-32
was shown to prolong the PKA response once it was activated
(Le Novere et al., 2008; Castro et al., 2013); in our experiments, a
cAMP response that has been lowered by the NO-cGMP path-
way may be insufficient to phosphorylate DARPP-32, while a
larger cAMP signal may phosphorylate more DARPP-32, there-
fore inhibit Phosphatase 1 more efficiently and thus potentiate
the net PKA effect. Such non-linear effects certainly determine
the integrative properties of striatal neurons and further model-
ing studies are needed to understand how this parameter comes
into play in the current learning theories.
DICHOTOMOUS cAMP RESPONSES IN MSNs
While the characteristic segregation of MSNs in two different
cell types is notoriously difficult to study on dissociated neurons,
biosensor imaging provides a measurement at the level of indi-
vidual mature neurons which can be identified on the basis of
their response to an agonist of either dopamine D1 or adeno-
sine A2A receptor (Castro et al., 2013). In this study, the TEpacVV
cAMP sensor was improved to increase its affinity for cAMP and
decrease it size, yielding a biosensor which proved highly efficient
to monitor cAMP signals in striatal neurons. This new biosensor
revealed the larger and desensitizing profile of the D1 response
which differed from the smaller and steady A2A response in D2
MSNs. These differences may be related to different regulations
at the level of receptor transduction and remain to be explored in
more details.
Our experiments also revealed a clear differences between
these two types of MSNs that lie downstream of the recep-
tors, which appeared when AC was transiently stimulated with
forskolin: the cAMP signals were stronger and lasted longer in
D2 MSNs than in D1 neurons. The AC activities do not explain
the differences observed in these cells because the rate of cAMP
production upon forskolin stimulation was similar in D1 and
D2 MSNs as indicated by a similar onset slope. This dichotomy
depends on differences in PDE activity since the broad-spectrum
PDE inhibitor, IBMX, suppressed the differences between MSNs.
Specific inhibition of PDE2 increased the cAMP signal exclu-
sively in D2 neurons, despite the expression of PDE2 in both
D1 and D2 neurons (Lin et al., 2010): this suggests that PDE2
is at the forefront in the degradation of cAMP in D2 neurons.
Transient cAMP responses recover faster in D1 neurons than in
D2 neurons, and this recovery is not affected by PDE2 inhibi-
tion suggesting that another PDE takes over PDE2 in D1 neurons.
Based on these results, we consider that amplitude and decay
of the cAMP signal are governed by a complex and non-linear
network, which may include subcellular compartmentation, in
which PDE2 appears as one critical element.Which PDE (or com-
bination) is at the forefront in D1 neurons remains to be deter-
mined, possibly PDE1A (Polli and Kincaid, 1994) and/or PDE10A
(Xie et al., 2006).
NO INCREASES cGMP LEVELS IN BOTH TYPES OF MSNs
This clear-cut segregation of MSNs into two populations with
different pharmacological profiles and PDE activities that was
observed for the cAMP/PKA signaling cascade was not seen at the
level of cGMP with the cGMP biosensor Cygnet: sGC stimulation
with NO donors produced a large and homogeneous increase in
cGMP levels in all MSNs, which is consistent with the high levels
of sGC present in both neuron types (Ding et al., 2004).
A tonic production of cGMP in response to the spontaneous
release of NO was reported in the hippocampus, optic nerve, tha-
lamus (Garthwaite et al., 2006; Hopper and Garthwaite, 2006;
Hepp et al., 2007), as well as in the striatum (Calabresi et al.,
1999; Galati et al., 2008). Our experiments in MSNs contrast
with these observations as no changes in cGMP concentration
was obtained upon bath application of ODQ or IBMX (Figure 1).
However, data in the striatum were obtained in quite different
experimental conditions: either the glutamatergic corticostriatal
afferent fibers were repeatedly stimulated which should activate
NOS interneurons (Calabresi et al., 1999), or the recordings were
performed in vivo where a number of other parameters can
directly or indirectly contribute to a tonic activation of these
NO-synthesizing cells (West and Grace, 2000, 2004; Galati et al.,
2008). This suggests that, in vivo, NOergic interneurons ton-
ically release NO which downregulate the dopamine-induced
PKA response of MSNs. Integrating this cellular mechanism
into the whole animal would be of paramount importance to
elucidate the clinical influence of compounds interfering with
NO/cGMP pathway in disabling disorders associated with the
striatum.
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